During 3 months of observation, 19% of study participants with moderate to severe, but stable, COPD overused their albuterol SABA inhalers more than half of the days.
According to a Childhood Asthma Management Program (CAMP) study, persistent childhood asthma may be linked to earlier development of COPD.
The discovery may help identify patients at higher risk for COPD progression, who might also show little benefit from standard treatments, according to the study presented at ATS 2016.
Severe emphysema patients treated with endobronchial coils saw a marked improvement in 6MWT distance after 12 months, according to a study published online by JAMA.
Symptomatic current or former smokers with preserved lung function, even if they do not meet the criteria for COPD, experience exacerbations and activity limitation.
GSK presented new data at ATS 2016 on analyses from the SUMMIT trial evaluating Breo Ellipta for patients with COPD.
Severe emphysema patients treated with Zephyr Endobronchial Valves (EBV) showed durable improvements in lung function, exercise capacity and quality of life at one year.
A new report commissioned by The Lancet Respiratory Medicine reveals that patients with lung disease encounter significant challenges in accessing care with high treatment costs and hospitals failing to provide recommended standards of care.
Findings demonstrated the superiority of Ultibro Breezhaler over the widely used inhaled corticosteroid/LABA combination on exacerbation outcomes.
Motivational interviewing is a feasible intervention that may reduce short-term readmissions for COPD patients, according to ATS 2016 research.
Belgian researchers say they have found a benchmark for significant improvement in COPD patient pulmonary rehabilitation: another 600 to 1,100 steps a day.
A study finds that pulmonary artery enlargement during hospitalization for COPD is linked to greater cardiac injury and worse clinical outcomes.
A new study shows that the symptoms of COPD may be worse in patients who also experience depression.
Daily use of the Aerobika device for three to four weeks produced significant improvements in clinical and patient reported outcomes for COPD.
New research suggests patients with COPD have an increased risk of renal impairment and renal failure.
In a recent study, mortality did not decrease in patients with COPD and cardiovascular disease risk who took fluticasone furoate, vilanterol, or a combination of the two.
Patients with early- and late-onset asthma overlapped with COPD showed decreased clinical function and worse overall prognosis in a recent study.
Advanced glycation endproducts (AGEs) accumulate differently in various parts of the body in people with COPD, according to research.
Patients with acute exacerbations of COPD had elevated YKL-40 levels, which suggests glycoprotein may have a pathogenic role in the disease, according to a study.
University of Toronto researchers show that levels of anxiety are up to three times higher in older adults with COPD than in patients without the condition.